Our very own Yansong Zhu was invited by the Optical Society (OSA) to blog for a workshop/incubator on Computational Modeling and Performance Metrics for Imaging System Design and Evaluation in Washington DC. His blog posts appear here and here.
We had a truly exciting and fruitful meeting on March 3rd for our BRAIN initiative effort. Our collaborators are converging to a couple of very promising approaches to enable transcranial, real time, in vivo imaging of brain network activity. When we first put in this grant, it had the appearance of science fiction, to improve temporal resolution in the in vivo imaging of neurotransmission from minutes in PET imaging, by ~4 orders of magnitude (!), to the scale of 10 milliseconds. But our results are very promising, and suggestive that this is indeed possible.
Our article on dynamic whole-body imaging has been ranked among top 10 most popular articles in the journal of Physics in Medicine & Biology (PMB) in 2016. The work was also featured on medicalphysicsweb in a piece titled “A clinical take on whole-body dynamic PET“. The work is creating excitement in its potential to transform routine clinical imaging, to enable dynamic PET imaging while still providing conventional whole-body standard uptake value (SUV) images.
Fereshteh Aalamifar successfully defended her PhD dissertation. The work, entitled “Co-Robotic Ultrasound Tomography: A New Paradigm for Quantitative Ultrasound Imaging” has been received very well so far, with multiple publications and patent application. It has been a real delight to work with Fereshteh, and we hope her work, naturally and effectively wedding robotics with tomographic imaging, will significantly impact clinical imaging in the years to come.
One of our ongoing efforts is to perform radiomics (texture/heterogeneity quantification) for the exciting prostate cancer tracer, PyL. Developed by the group of Dr. Martin Pomper, PyL (a PSMA-targeted PET imaging agent; see video below) is now licensed to Progenics which works closely with our division to further establish clinical use of this tracer.